Philips: Hospital Tenders With the Winner Built In

The Philips FCPA case announced in 2023 brought an agreement to pay more than $62 million over alleged distributor-discount and hospital-tender misconduct in China. The Securities and Exchange Commission’s announcement described employees and intermediaries influencing the specifications hospitals used to buy medical diagnostic equipment, then preparing additional bids to make the competition look real. Someone inside sales, a distributor or the tender team could recognize the arrangement before it ever appeared as a problem in the accounts.

Philips had already faced an action under the Foreign Corrupt Practices Act over public health care purchases in Poland. That earlier case concerned alleged payments to officials who helped shape equipment tenders and, in some instances, decided who won them. The later China case returned to the same uncomfortable question: who was writing the terms of the competition, and who benefited from the result?

Poland’s Medical Equipment Tenders Favored Philips Specifications

The Securities and Exchange Commission’s April 5, 2013 order alleged that employees of Philips Polska, the Polish subsidiary, made improper payments to public healthcare officials in at least 30 transactions from 1999 through 2007. The purpose was to increase the likelihood that Philips would win public tenders for medical equipment. The case was against the Netherlands-based parent, Koninklijke Philips Electronics N.V., whose accounts included the subsidiary’s financial statements.

According to the order, Philips Poland representatives supplied the technical specifications of Philips equipment to officials drafting the tenders. Those officials incorporated the specifications into the requirements. Some of the same officials also decided which supplier received the contract, and employees allegedly paid them when Philips won.

The alleged payments usually amounted to 3% to 8% of the contracts’ net value. Employees sometimes kept a portion themselves and often used a third-party agent to help arrange the payments. As alleged, this was procurement influence before the contract award, followed by a payment tied to the result.

For a competing equipment supplier, the specification is where a sales opportunity can disappear. A requirement written around the favored product can make the winner look like the supplier that simply met the hospital’s needs. We see the absurdity in the SEC’s account: the sales side allegedly helped write the test its own equipment would pass, and officials taking the payments could also choose the winner.

The agency alleged that the payments were recorded as legitimate expenses, sometimes supported by false documents created by employees or third parties. Those descriptions then entered the parent’s consolidated accounts. A person who knew what the agent actually did could explain what the expense description concealed.

China’s Distributor Discounts and Manufactured Competition

The Securities and Exchange Commission’s May 11, 2023 announcement described a later action against Koninklijke Philips N.V. involving subsidiaries grouped as Philips China. The alleged conduct connected special distributor discounts with efforts to influence hospital purchases of medical diagnostic equipment. The agency again resolved books-and-records and internal-accounting-controls charges.

The agency alleged that special price discounts created a risk that excessive distributor margins could fund improper payments to government employees. That risk makes the margin a commercial link between the equipment sale and a possible payment outside the manufacturer’s own expense accounts.

That is why distributor discounts need to be understood alongside the customer price. A distributor buys from the supplier and resells to the customer, so the supplier’s approved price and the hospital’s actual price tell different parts of the transaction. For a sales or finance insider, the useful connection is the discount approval, the margin left with the distributor and what that intermediary did to win the hospital’s business.

The agency alleged that a district sales manager provided funds to a hospital director in return for help with procurement. In another instance, employees allegedly discussed technical specifications with hospital directors so that only Philips China and two other manufacturers would qualify. These were concrete decisions about who could compete, made before the hospital selected a supplier.

The alleged manipulation continued into the competing bids. Employees, distributors or sub-dealers prepared additional bids using other manufacturers’ products to create the appearance of legitimate public tenders and meet the minimum-bid requirement under Chinese law. The hospital could have multiple bids in its file while the same commercial interests had helped prepare them.

We see a competition being supplied along with the product. The person who knows who drafted the bids may have a clearer view of the sale than someone who sees only the final tender file.

Why Hospital Purchasing Gives the Intermediary Leverage

Public hospital purchasing puts medical judgment and purchasing authority in the same commercial relationship. In a 2015 pharmaceutical-industry speech, the Securities and Exchange Commission’s enforcement director described doctors, pharmacists and administrators who often decide what public hospitals buy. He also explained how a distributor’s margin can create a cash fund for bribes, with the extra layer of cash flow helping payments appear as ordinary expenses.

The Philips cases make that industry problem tangible. In the Polish allegations, the official could influence both the specifications and the award. In the China allegations, hospital assistance and prepared bids again reached into the purchasing decision. The sales relationship mattered because it reached people with power over public spending.

Fresenius Medical Care supplies a close comparison from the same industry. The Securities and Exchange Commission’s order alleged manipulation of a Spanish public-hospital tender in which the supplier helped prepare both the technical requirements and the scoring:

The scoring method matters as much as the equipment specification. A tender can favor a supplier through the features it requires, the weight it gives them and the scores proposed for the competing products. The Fresenius example shows why someone who saw the drafts may understand the purchase differently from someone reading the published requirements.

A 2022 Journal of Forensic and Investigative Accounting paper, Fresenius Medical Care: A Case Study on the FCPA, traces another connection in China: bonuses to publicly employed doctors with influence over clinic procurement were paid when Fresenius received hospital payments. The study describes those bonuses being recorded as center marketing fees.

The comparison connects the hospital payment and the doctor’s influence to the expense label. For a medical-device whistleblower, knowing why the payment was made can be more revealing than the name assigned to it in the ledger.

The First Audit Missed the Payments

Philips’s initial internal audit failed to discover the improper payments described in the Polish case, according to the Securities and Exchange Commission’s order. The company conducted that audit in 2007 after Polish authorities searched its offices. Philips changed local management and revised internal controls, yet the payments remained undiscovered by that review.

The order says a later investigation, following a Polish indictment, supported the payment allegations and exposed inaccurate accounts and failed controls. Philips reported its investigation to the SEC and the Justice Department in early 2010 and shared the results as the work progressed. The order described subsequent reforms covering third-party checks, centralized contract administration, contract review and verification of payments.

Those reforms addressed the business channels through which the Polish payments allegedly moved. But in its later China announcement, the Securities and Exchange Commission said Philips had still failed to implement sufficient accounting controls for medical-technology sales there despite the earlier remediation.

For an insider, that distinction makes the response to an internal warning part of the story. A revised approval form or new training program tells us what management changed. The later discount, payment and tender records show how the next sale actually proceeded.

What Conduct Can Violate the FCPA?

False expense records and accounting controls that fail to detect improper payments can violate the Foreign Corrupt Practices Act. Both Philips actions addressed those accounting charges. In the Polish order, the books-and-records charge concerned payments described as legitimate expenses and supported by falsified records. The internal-controls charge concerned the system that failed to detect or prevent those payments and false entries.

The distinction matters to someone who sees only part of a sale. An accountant may know that an invoice describes work nobody performed. A sales employee may know why a discount was requested, while a tender specialist knows who supplied the specification or prepared the competing bid. We connect those observations to the approval, the payment and the account in which the transaction appeared.

The Polish order also faulted a compliance and training program that did not match the extent of Philips’s international operations. The China announcement returned to controls proportionate to the business. Read together, the agency’s accounts make the local sales process central to understanding the parent’s accounting problem.

The Settlement Money and Whistleblower Rewards

The Polish order required Philips to give up $3,120,597 in gains, but imposed no civil penalty because of the company’s cooperation. In the later China resolution, Philips agreed to a $15 million civil penalty. We see the cost of controls that failed again: cooperation spared Philips a penalty in Poland, then it faced one in China.

For an eligible whistleblower, SEC whistleblower awards can total 10% to 30% of qualifying sanctions collected. Our whistleblower experts assess how your knowledge of the tender, distributor or accounting decision could contribute to a case and which award program fits.

A whistleblower case under the False Claims Act can pay 15% to 30% of what the government recovers. That is a separate kind of case from the Philips SEC actions discussed here. We work through that distinction with you against the conduct you know.

You Know How the Hospital Chose the Supplier

If you know who shaped a hospital tender, why a distributor received a special discount or what a payment description concealed, talk with our whistleblower experts about the sale. We turn the decisions you can explain into your strongest case, bring in Foreign Corrupt Practices Act whistleblower lawyers who understand medical-equipment sales and public procurement, and stay beside you through the process.